We expect the leading medical devices provider
) to beat expectations when it reports fiscal 2014 first quarter
results after the closing bell on Oct 10.
Why a Likely Positive Surprise?
Our proven model shows that AngioDynamics is likely to beat
earnings estimates because it has the right combination of two
Positive Zacks ESP:
, the difference between the Most Accurate estimate of 4 cents
and the Zacks Consensus Estimate of 3 cents, stands at +33.33%.
Zacks Rank #3 (Hold):
ANGO currently retains a Zacks Rank #3 (Hold).
The combination of the stock's Zacks Rank #3 (Hold) and +33.33%
ESP makes us confident of a positive earnings beat on Oct 10.
What is Driving the Better than Expected
AngioDynamics enjoys leading market share in several of its
operating segments including angiographic products and
thrombolytic catheters and products. The market served by ANGO is
in excess of $1 billion, and continues to grow.
AngioDynamics has delivered solid earnings results in the fourth
quarter of fiscal 2013. It has reported more than twofold
year-over-year increase in adjusted earnings to 7 cents per share
for the quarter, surpassing the Zacks Consensus Estimate by 2
cents. For fiscal 2013, adjusted earnings surged 66.7% to 35
cents per share and beat the Zacks Consensus Estimate by a penny
AngioDynamics expects fiscal 2014 revenues in the range of $346
million-$352 million, up 3% at the top range of the previous
guidance. Adjusted earnings per share are expected in the range
of 31 cents to 35 cents for the fiscal year, taking into account
the impact from the medical device tax.
Other Stocks to Consider
AngioDynamics is not the only bullish company this earnings
season. We also see likely earnings beats coming from the
following industry peers:
): Earnings ESP of +15.39% and Zacks Rank #2 (Buy).
Sunshine Heart Inc.
): Earnings ESP of +32.50% and Zacks Rank #3 (Hold).
): Earnings ESP of +1.25% and Zacks Rank #3 (Hold).
ANGIODYNAMICS (ANGO): Free Stock Analysis
DEXCOM INC (DXCM): Free Stock Analysis Report
SUNSHINE HEART (SSH): Free Stock Analysis
TECHNE CORP (TECH): Free Stock Analysis
To read this article on Zacks.com click here.